title: [Screening and treatment of hyperlipidemias in Israel].
abstract: Hyperlipidemias are a major risk factor for cardiovascular disease. Screening and treatment guidelines for the metabolic disorders associated with them have been adopted and published by the Israel Atherosclerosis Society. We examined the frequency of plasma lipid determinations and treatment of hyperlipidemia by a sample of family practitioners, primary physicians, cardiologists and internists working in ambulatory, primary medical care who filled out questionnaires for consecutive adult clinic patients. Of 2015 patients, 1029 (51%) were reported to be free of cardiovascular disease or its risk factors, 606 (30%) had at least 1 risk factor, 171 (8%) had peripheral or cerebrovascular atherosclerotic disease, 131 (7%) had had a myocardial infarction and 78 (4%) had undergone coronary angioplasty or bypass surgery. Although the frequency of determinations of total HDL and LDL cholesterol increased from those without a risk factor to those after bypass surgery, the overall rates were lower than expected in all groups. With regard to risk factors, in those with a family history of cardiovascular disease lipid determinations were done most frequently, approaching the frequency in the bypass group. Combined hypercholesterolemia and hypertriglyceridemia was the most common metabolic aberration in all categories. The rate of drug therapy increased from those with no risk factor to those after bypass surgery. Therapy with resin was reported in 3-14%, fibric acid derivatives in 29-53% and statins in 33-57% of the various patient groups. Again, the drug therapy profile of the group with a positive family history was similar to that of the bypass group.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Lipid and Atherosclerosis Research Institute, Haim Sheba Medical Center, Tel Hashomer.
authors.forename: E
authors.initials: E
authors.lastname: Sehayek
authors.forename: S
authors.initials: S
authors.lastname: Eisenberg
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000453:epidemiology / Q000209:etiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D007557:Israel / Q000453:epidemiology; D008055:Lipids / Q000097:blood; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids